{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:14:38Z","timestamp":1786976078056,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd007110.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000}}],"reference-count":229,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007110.pub4","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T06:46:38Z","timestamp":1733121998000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early-stage Hodgkin\u2019s lymphoma"],"prefix":"10.1002","volume":"2024","author":[{"given":"Marius","family":"Goldkuhle","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Institute of Public Health; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Kreuzberger","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Institute of Public Health; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"},{"name":"Department of Hematology and Stem Cell Transplantation; West German Cancer Center, University Hospital Essen, University of Duisburg-Essen; Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A","family":"Eichenauer","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Specht","sequence":"additional","affiliation":[{"name":"Department of Oncology; University of Copenhagen \u2013 Rigshospitalet; Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Monsef","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Institute of Public Health; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Institute of Public Health; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"key":"10.1002\/14651858.CD007110.pub4-BIB0001|cit1","unstructured":"Bloomfield CD Pajak TF Glicksman AS Gottlieb AJ Coleman M Nissen NI Chemotherapy and combined modality therapy for Hodgkin's disease: a progress report on Cancer and Leukemia Group B studies Cancer Treatment Reports 1982 66 4 835 46"},{"issue":"11 Suppl","key":"10.1002\/14651858.CD007110.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"abstract 814","DOI":"10.1182\/blood.V106.11.814.814","article-title":"Comparison of three radiation dose levels after EBVP regimen in favourable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): preliminary results of EORTC-GELA H9-F trial","volume":"106","author":"Eghbali","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0003|cit3","doi-asserted-by":"crossref","unstructured":"Noordijk EM Thomas J Ferm\u00e9 C Van't Veer MB Brice P Divine M First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma ASCO Annual Meeting Presentation Slides 2005","DOI":"10.1200\/jco.2005.23.16_suppl.6505"},{"issue":"Suppl","key":"10.1002\/14651858.CD007110.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"abstract 6505","DOI":"10.1200\/jco.2005.23.16_suppl.6505","article-title":"First results of EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favourable or unfavourable early stage Hodgkin's lymphoma","volume":"23","author":"Noordijk","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0005|cit5","unstructured":"Thomas J Ferm\u00e9 C Noordijk EM Eghbali H Henry-Amar M The EORTC-GELA treatment strategy in clinical stages I\u2013II HL: results of the H9-F and H9-U trials International Symposium on Hodgkin Lymphoma, Cologne, Presentation 2007"},{"issue":"5","key":"10.1002\/14651858.CD007110.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.ijrobp.2017.10.015","article-title":"Comparison of 36 Gy, 20 Gy, or no radiation therapy after 6 cycles of EBVP chemotherapy and complete remission in early-stage Hodgkin lymphoma without risk factors: results of the EORTC-GELA H9-F intergroup randomized trial","volume":"100","author":"Thomas","year":"2018","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"Supp 65","key":"10.1002\/14651858.CD007110.pub4-BIB0007|cit7","first-page":"40","article-title":"Six cycles of EBVP followed by 36 Gy involved field irradiation vs. no irradiation in favourable supradiaphragmatic clinical stages III Hodgkin's lymphoma: the EORTC-GELA strategy in 771 patients (H9-F trial-20982) [Abstract AE11a]","volume":"73","author":"Thomas","year":"2004","journal-title":"European Journal of Haematology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD007110.pub4-BIB0008|cit8","first-page":"27","article-title":"Results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma","volume":"92","author":"Thomas","year":"2007","journal-title":"Haematologica"},{"issue":"16","key":"10.1002\/14651858.CD007110.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andre","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1182\/blood.V120.21.549.549","article-title":"Interim analysis of the randomized EORTC\/LYSA\/FIl Intergroup H10 trial on early PET-scan driven treatment adaptation in stage I\/II Hodgkin lymphoma","volume":"120","author":"Andre","year":"2012","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0011|cit11","unstructured":"Andre MP An update on the EORTC \/ LYSA \/ FIL H10 trial 9th International Symposium on Hodgkin Lymphoma; 2013 Oct 12-15; Cologne, Germany 2013"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007110.pub4-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/hon.2879","article-title":"Relapses in interim PET negative limited stage Hodgkin lymphoma patients receiving ABVD with or without radiotherapy-analysis of EORTC\/FIL\/LYSA H10 and UK NCRI Rapid trials","volume":"39","author":"Aurer","year":"2021","journal-title":"Hematological Oncology"},{"issue":"13","key":"10.1002\/14651858.CD007110.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood-2017-07-795476","article-title":"Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD007110.pub4-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/JCO.23.01745","article-title":"Long-term follow-up of the response-adapted intergroup EORTC\/LYSA\/FIL H10 trial for localized Hodgkin lymphoma","volume":"42","author":"Federico","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD007110.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/bjh.18594","article-title":"Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy \u2013 a joint analysis of EORTC\/LYSA\/FIL H10 and NCRI RAPID trials","volume":"200","author":"Fiaccadori","year":"2023","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/hon.104_2630","article-title":"Outcome and treatment of relapsing early PET negative patients included in the EORTC\/LYSA\/FIL H10 trial on stages I\/II Hodgkin lymphoma","volume":"37","author":"Gac","year":"2019","journal-title":"Hematological Oncology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007110.pub4-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/hon.2880","article-title":"Baseline maximum tumour diameter is associated with event-free survival for PET-negative patients with limited-stage Hodgkin lymphoma: analysis of the H10 and Rapid trials","volume":"39","author":"Phillips","year":"2021","journal-title":"Hematological Oncology"},{"issue":"12","key":"10.1002\/14651858.CD007110.pub4-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD007110.pub4-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.3324\/haematol.2021.280004","article-title":"High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline","volume":"107","author":"Rossi","year":"2022","journal-title":"Haematologica"},{"issue":"16","key":"10.1002\/14651858.CD007110.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andre","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1182\/blood.V120.21.549.549","article-title":"Interim analysis of the randomized EORTC\/LYSA\/FIl intergroup H10 trial on early PET-scan driven treatment adaptation in stage I\/II Hodgkin lymphoma","volume":"120","author":"Andre","year":"2012","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0022|cit22","unstructured":"Andre MP An update on the EORTC \/ LYSA \/ FIL H10 trial 9th International Symposium on Hodgkin Lymphoma; 2013 Oct 12-15; Cologne, Germany 2013"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007110.pub4-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/hon.2879","article-title":"Relapses in interim PET negative limited stage Hodgkin lymphoma patients receiving ABVD with or without radiotherapy-analysis of EORTC\/FIL\/LYSA H10 and UK NCRI Rapid trials","volume":"39","author":"Aurer","year":"2021","journal-title":"Hematological Oncology"},{"issue":"13","key":"10.1002\/14651858.CD007110.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood-2017-07-795476","article-title":"Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD007110.pub4-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/JCO.23.01745","article-title":"Long-term follow-up of the response-adapted intergroup EORTC\/LYSA\/FIL H10 trial for localized Hodgkin lymphoma","volume":"42","author":"Federico","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD007110.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/bjh.18594","article-title":"Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy \u2013 a joint analysis of EORTC\/LYSA\/FIL H10 and NCRI RAPID trials","volume":"200","author":"Fiaccadori","year":"2023","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/hon.104_2630","article-title":"Outcome and treatment of relapsing early PET negative patients included in the EORTC\/LYSA\/FIL H10 trial on stages I\/II Hodgkin lymphoma","volume":"37","author":"Gac","year":"2019","journal-title":"Hematological Oncology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007110.pub4-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/hon.2880","article-title":"Baseline maximum tumour diameter is associated with event-free survival for PET-negative patients with limited-stage Hodgkin lymphoma: analysis of the H10 and rapid trials","volume":"39","author":"Phillips","year":"2021","journal-title":"Hematological Oncology"},{"issue":"12","key":"10.1002\/14651858.CD007110.pub4-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD007110.pub4-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.3324\/haematol.2021.280004","article-title":"High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline","volume":"107","author":"Rossi","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"10.1002\/14651858.CD007110.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijrobp.2019.06.445","article-title":"Consolidating involved field radiotherapy prevents early and local recurrences in early stage Hodgkin lymphoma","volume":"105","author":"Baues","year":"2019","journal-title":"International Journal of Radiation Oncology Biology Physics"},{"issue":"4","key":"10.1002\/14651858.CD007110.pub4-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.ijrobp.2021.07.1697","article-title":"Involved-field radiation therapy prevents recurrences in the early stages of Hodgkin lymphoma in PET-negative patients after ABVD chemotherapy: relapse analysis of GHSG phase 3 HD16 trial","volume":"111","author":"Baues","year":"2021","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"1","key":"10.1002\/14651858.CD007110.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijrobp.2019.06.380","article-title":"PET-guided treatment of early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase 3 trial HD16 by the GHSG","volume":"105","author":"Eich","year":"2019","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"6","key":"10.1002\/14651858.CD007110.pub4-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/blood.2023019939","article-title":"Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies","volume":"142","author":"Eichenauer","year":"2023","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01.HS9.0000890648.99383.b7","article-title":"Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies","volume":"6","author":"Eichenauer","year":"2022","journal-title":"Hemasphere"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1182\/blood-2021-145427","article-title":"Treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD16 study","volume":"138","author":"Eichenauer","year":"2021","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0037|cit37","first-page":"819","article-title":"PET after 2 cycles of ABVD in patients with early-stage favourable Hodgkin lymphoma treated within the phase 3 GHSG HD16 study","volume":"-","author":"Fuchs","year":"2019","journal-title":"EHA Library"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007110.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2018-99-114519","article-title":"PET-guided treatment of early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase 3 trial HD16 by the German Hodgkin Study Group","volume":"132","author":"Fuchs","year":"2018","journal-title":"Blood"},{"issue":"31","key":"10.1002\/14651858.CD007110.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1159\/000502425","article-title":"PET positivity after 2 cycles of ABVD is a risk factor in patients with early-stage favorable Hodgkin lymphoma treated in the phase 3 GHSG HD16 study","volume":"42","author":"Fuchs","year":"2019","journal-title":"Oncology Research and Treatment"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41375-023-02064-y","article-title":"Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma","volume":"16","author":"Fuchs","year":"2023","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41375-023-02064-y","article-title":"Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma","volume":"16","author":"Fuchs","year":"2023","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/blood-2021-152260","article-title":"PET-guided treatment in patients with early-stage favorable Hodgkin lymphoma: follow-up analysis of the HD16 trial by the German Hodgkin Study Group","volume":"138","author":"Fuchs","year":"2021","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/blood-2021-152260","article-title":"PET-guided treatment in patients with early-stage favorable Hodgkin lymphoma: follow-up analysis of the HD16 trial by the German Hodgkin Study Group","volume":"138","author":"Fuchs","year":"2021","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000521004","article-title":"PET-guided treatment in patients with early-stage favorable Hodgkin lymphoma: follow-up analysis of the HD16 trial by the German Hodgkin Study Group","volume":"45","author":"Jacob","year":"2022","journal-title":"Oncology Research and Treatment"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000521004","article-title":"PET-guided treatment in patients with early-stage favorable Hodgkin lymphoma: follow-up analysis of the HD16 trial by the German Hodgkin Study Group","volume":"45","author":"Jacob","year":"2022","journal-title":"Oncology Research and Treatment"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/01.HS9.0000890956.78190.fc","article-title":"The status quo of involved-field radiotherapy \u2013 quality analysis of radiotherapy in the GHSG HD 16","volume":"6","author":"Oertel","year":"2022","journal-title":"Hemasphere"},{"issue":"3","key":"10.1002\/14651858.CD007110.pub4-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"101169","DOI":"10.1016\/j.adro.2022.101169","article-title":"Radiation therapy in the German Hodgkin Study Group HD 16 and HD 17 trials: quality assurance and dosimetric analysis for Hodgkin lymphoma in the modern era","volume":"8","author":"Oertel","year":"2023","journal-title":"Advances in Radiation Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007110.pub4-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1186\/s12885-022-09758-z","article-title":"Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin lymphoma \u2013 data from the prospective, multicenter phase III HD16 trial","volume":"22","author":"Heek","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000510995","article-title":"Positron emission tomography guided omission of radiotherapy in early-stage unfavorable Hodgkin lymphoma: final results of the international, randomized Phase III HD17 trial by the German Hodgkin Study Group","volume":"43","author":"Borchmann","year":"2020","journal-title":"Oncology Research and Treatment"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000510995","article-title":"Positron emission tomography guided omission of radiotherapy in early-stage unfavorable Hodgkin lymphoma: final results of the international, randomized Phase III HD17 trial by the German Hodgkin Study Group","volume":"43","author":"Borchmann","year":"2020","journal-title":"Oncology Research and Treatment"},{"issue":"6","key":"10.1002\/14651858.CD007110.pub4-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/blood.2023019939","article-title":"Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies","volume":"142","author":"Eichenauer","year":"2023","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01.HS9.0000890648.99383.b7","article-title":"Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin Lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies","volume":"6","author":"Eichenauer","year":"2022","journal-title":"Hemasphere"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0054|cit54","unstructured":"HD17 for intermediate stages \u00ad treatment optimization trial in the first\u00adline treatment of intermediate stage Hodgkin lymphoma clinicaltrials.gov\/study\/NCT01356680"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"1183906","DOI":"10.3389\/fonc.2023.1183906","article-title":"Radiation doses to mediastinal organs at risk in early-stage unfavorable Hodgkin lymphoma \u2013 a risk stratified analysis of the GHSG HD17 trial","volume":"13","author":"Oertel","year":"2023","journal-title":"Frontiers in Oncology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"1183906","DOI":"10.3389\/fonc.2023.1183906","article-title":"Radiation doses to mediastinal organs at risk in early-stage unfavorable Hodgkin lymphoma \u2013 a risk stratified analysis of the GHSG HD17 trial","volume":"13","author":"Oertel","year":"2023","journal-title":"Frontiers in Oncology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0057|cit57","first-page":"42","article-title":"Estimating the dosimetric benefit of involved node radiotherapy in comparison to involved-field radiotherapy \u2013 implications from the GHSG HD17 trial","volume":"6","author":"Oertel","year":"2022","journal-title":"Hemasphere"},{"issue":"3","key":"10.1002\/14651858.CD007110.pub4-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"101169","DOI":"10.1016\/j.adro.2022.101169","article-title":"Radiation therapy in the German Hodgkin Study Group HD 16 and HD 17 trials: quality assurance and dosimetric analysis for Hodgkin lymphoma in the modern era","volume":"8","author":"Oertel","year":"2023","journal-title":"Advances in Radiation Oncology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"658358","DOI":"10.3389\/fonc.2021.658358","article-title":"Involved site radiotherapy extends time to premature menopause in infra-diaphragmatic female Hodgkin lymphoma patients \u2013 an analysis of GHSG HD14- and HD17-patients","volume":"11","author":"Rosenbrock","year":"2021","journal-title":"Frontiers in Oncology"},{"issue":"6","key":"10.1002\/14651858.CD007110.pub4-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/ejh.14093","article-title":"Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable Hodgkin lymphoma: data from the phase III HD17 trial","volume":"111","author":"Heek","year":"2023","journal-title":"European Journal of Haematology"},{"issue":"11","key":"10.1002\/14651858.CD007110.pub4-BIB0061|cit61","first-page":"26a","article-title":"A randomized phase III comparison of single-modality ABVD with a strategy that includes radiation therapy in patients with early-stage Hodgkin's disease: the HD-6 trial of the National Cancer Institute of Canada Clinical Trials Group (Eastern Cooperative Oncology Group Trial HD06)","volume":"11","author":"Meyer","year":"2003","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood.V118.21.590.590","article-title":"Final analysis of a randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy (RT) in patients with limited-stage Hodgkin lymphoma (HL): NCIC CTG\/ECOG HD.6","volume":"118","author":"Meyer","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1002\/14651858.CD007110.pub4-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2005.09.085","article-title":"Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group","volume":"23","author":"Meyer","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD007110.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1111961","article-title":"ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma","volume":"366","author":"Meyer","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD007110.pub4-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s00520-023-07717-3","article-title":"Health-related quality of life in early-stage Hodgkin lymphoma: a longitudinal analysis of the ABVD arm in the randomized controlled trial HD.6","volume":"31","author":"Mian","year":"2023","journal-title":"Supportive Care in Cancer"},{"issue":"5","key":"10.1002\/14651858.CD007110.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s11912-006-0057-x","article-title":"Clinical trials report. Comparison of ABVD chemotherapy and a regimen including radiation therapy in patients with limited-stage non-Hodgkin's lymphoma","volume":"8","author":"Portlock","year":"2006","journal-title":"Current Oncology Reports"},{"issue":"12","key":"10.1002\/14651858.CD007110.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1182\/blood-2004-04-1311","article-title":"Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA non-bulky Hodgkin disease","volume":"104","author":"Straus","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD007110.pub4-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/MPH.0000000000000483","article-title":"RAPID trial demonstrates low positive predictive value of interim FDG-PET in early-stage Hodgkin lymphoma after three cycles of ABVD","volume":"38","author":"Adams","year":"2016","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007110.pub4-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/hon.2879","article-title":"Relapses in interim PET negative limited stage Hodgkin lymphoma patients receiving ABVD with or without radiotherapy-analysis of EORTC\/FIL\/LYSA H10 and UK NCRI rapid trials","volume":"39","author":"Aurer","year":"2021","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0070|cit70","first-page":"24","article-title":"Treatment escalation in patients with early stage Hodgkin lymphoma and a positive PET scan after initial chemotherapy is not always required: subsidiary analysis of the UK NCRI Rapid study","volume":"181","author":"Barrington","year":"2018","journal-title":"British Journal of Haematology"},{"issue":"20","key":"10.1002\/14651858.CD007110.pub4-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.18.01799","article-title":"Positron emission tomography score has greater prognostic significance than pretreatment risk stratification in early-stage Hodgkin lymphoma in the UK RAPID Study","volume":"37","author":"Barrington","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"32","key":"10.1002\/14651858.CD007110.pub4-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1200\/JCO.21.00408","article-title":"Predicted risks of cardiovascular disease following chemotherapy and radiotherapy in the UK NCRI RAPID Trial of positron emission tomography-directed therapy for early-stage Hodgkin lymphoma","volume":"39","author":"Cutter","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD007110.pub4-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/bjh.18594","article-title":"Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy \u2013 a joint analysis of EORTC\/LYSA\/FIL H10 and NCRI RAPID trials","volume":"200","author":"Fiaccadori","year":"2023","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD007110.pub4-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"e0231027","DOI":"10.1371\/journal.pone.0231027","article-title":"Quantitative assessment of interim PET in Hodgkin lymphoma: an evaluation of the qPET method in adult patients in the RAPID trial","volume":"15","author":"Georgi","year":"2020","journal-title":"PLOS One"},{"issue":"1","key":"10.1002\/14651858.CD007110.pub4-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1182\/bloodadvances.2019001023","article-title":"Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I\/IIA Hodgkin lymphoma","volume":"4","author":"Illidge","year":"2020","journal-title":"Blood Advances"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007110.pub4-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1182\/blood-2020-136318","article-title":"Enhanced outcome prediction in early stage classical Hodgkin lymphoma using pre-treatment biomarkers and interim PET (BioPET): a sub-analysis of the UK NCRI RAPID trial","volume":"136","author":"Linton","year":"2020","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007110.pub4-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/hon.2880","article-title":"Baseline maximum tumour diameter is associated with event-free survival for PET-negative patients with limited-stage Hodgkin lymphoma: analysis of the H10 and rapid trials","volume":"39","author":"Phillips","year":"2021","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood.V120.21.547.547","article-title":"Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a 'negative' PET scan after 3 cycles ABVD. Results of the UK NCRI RAPID trial","volume":"120","author":"Radford","year":"2012","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007110.pub4-BIB0079|cit79","first-page":"13","article-title":"Prognostic performance of pre-treatment EORTC, GHSG and IPI risk factors and post-chemotherapy PET response in the UK NCRI RAPID TRIAL in early stage Hodgkin lymphoma (HL)","volume":"98","author":"Radford","year":"2013","journal-title":"Haematologica"},{"issue":"17","key":"10.1002\/14651858.CD007110.pub4-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD007110.pub4-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood.V112.11.369.369","article-title":"Results of the 2nd planned interim analysis of the Rapid trial (involved field radiotherapy versus no further treatment) in patients with clinical stages 1a and 2a Hodgkin lymphoma and a 'negative' FDG-PET scan after 3 cycles ABVD","volume":"112","author":"Radford","year":"2008","journal-title":"Blood"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD007110.pub4-BIB0082|cit82","first-page":"16","article-title":"Results of the 3rd planned interim analysis of the UK NCRI RAPID trial (involved field radiotherapy versus no further treatment) in patients with clinical stages IA\/IIA Hodgkin lymphoma and a 'negative' 18 FDG-PET scan after 3 cycles ABVD","volume":"95","author":"Radford","year":"2010","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0083|cit83","unstructured":"Radford J Update on the NCRI RAPID trial 9th International Symposium on Hodgkin Lymphoma; 2013 Oct 12-15; Cologne, Germany 2013"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD007110.pub4-BIB0084|cit84","first-page":"32","article-title":"Interim results of a UK NCRI randomized trial comparing involved field radiotherapy with no further treatment after 3 cycles ABVD and a negative pet scan in clinical stages IA\/IIA Hodgkin lymphoma","volume":"92","author":"Radford","year":"2007","journal-title":"Haematologica"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD007110.pub4-BIB0085|cit85","first-page":"abstract 528a","article-title":"Bulky Hodgkin's disease (B-HD): treatment with an initial 7 drug chemotherapy (CT) delivered over 12 weeks followed by high dose extended field irradiation (EF-RT). Seven year results of the GOELAMS H90M multicentric randomized trial","volume":"94","author":"Andrieu","year":"1999","journal-title":"Blood"},{"issue":"8 Suppl 16","key":"10.1002\/14651858.CD007110.pub4-BIB0086|cit86","first-page":"14","article-title":"Final analysis of a randomized phase II study with prednisone, vinblastine, doxorubicin, and gemcitabine in patients with early unfavorable Hodgkin lymphoma-PVAG-14 Pilot","volume":"12","year":"2014","journal-title":"Clinical Advances in Hematology and Oncology"},{"issue":"4","key":"10.1002\/14651858.CD007110.pub4-BIB0087|cit87","first-page":"835","article-title":"Chemotherapy and combined modality therapy for Hodgkin's disease: a progress report on Cancer and Leukemia Group B studies","volume":"66","author":"Bloomfield","year":"1982","journal-title":"Cancer Treatment Reports"},{"issue":"7","key":"10.1002\/14651858.CD007110.pub4-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.2006.07.0722","article-title":"CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"25","author":"Bonnet","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD007110.pub4-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1200\/JCO.21.01281","article-title":"Brentuximab Vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial","volume":"41","author":"Fornecker","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007110.pub4-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/annonc\/5.suppl_2.S101","article-title":"Early-stage Hodgkin's disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy","volume":"5","author":"Brusamolino","year":"1994","journal-title":"Annals of Oncology"},{"issue":"11","key":"10.1002\/14651858.CD007110.pub4-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1080\/10428194.2018.1435872","article-title":"Long-term results of the AIEOP MH'96 childhood Hodgkin's lymphoma trial and focus on significance of response to chemotherapy and its implication in low risk patients to avoid radiotherapy","volume":"59","author":"Burnelli","year":"2018","journal-title":"Leukemia and Lymphoma"},{"issue":"5","key":"10.1002\/14651858.CD007110.pub4-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1200\/JCO.22.00947","article-title":"Positron emission tomography-adapted therapy in bulky stage I\/II classic Hodgkin lymphoma: CALGB 50801 (Alliance)","volume":"41","author":"LaCasce","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007110.pub4-BIB0093|cit93","first-page":"72","article-title":"Combined modality therapy in early stage Hodgkin's disease \u2013 preliminary results of a clinical trial","volume":"29","author":"Cheveresan","year":"1998","journal-title":"Leukemia and Lymphoma"},{"issue":"11-12","key":"10.1002\/14651858.CD007110.pub4-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/0277-5379(90)90265-U","article-title":"Chemotherapy alone for the treatment of early-stage Hodgkin's disease","volume":"26","author":"Cimino","year":"1990","journal-title":"European Journal of Cancer"},{"issue":"11","key":"10.1002\/14651858.CD007110.pub4-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/0959-8049(92)90018-W","article-title":"The EORTC trials for limited stage Hodgkin's disease","volume":"28A","author":"Cosset","year":"1992","journal-title":"European Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD007110.pub4-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/bjh.14734","article-title":"Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET\/CT is beneficial: a prospective multicentre trial of 355 patients","volume":"178","author":"Dann","year":"2017","journal-title":"British Journal of Haematology"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD007110.pub4-BIB0097|cit97","first-page":"abstract 386a","article-title":"Treatment of CS IA to IIIB non-bulky Hodgkin's disease (NB-HD) with 3 cycles of chemotherapy (CT) (ABVD vs EBVM) followed by high dose irradiation (RT). Results of the GOELAMS H90-NM multicentre randomized trial","volume":"94","author":"Desablens","year":"1999","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD007110.pub4-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0360-3016(98)90013-X","article-title":"Initial chemotherapy and low-dose radiation in limited fields in childhood Hodgkin's disease: results of a joint cooperative study by the French Society of Pediatric Oncology (SFOP) and H\u00f4pital Saint-Louis, Paris","volume":"15","author":"Dionet","year":"1988","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"11","key":"10.1002\/14651858.CD007110.pub4-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"abstract A","DOI":"10.1182\/blood.V106.11.813.813","article-title":"Four ABVD and involved\u00ad field radiotherapy in unfavorable supradiaphragmatic clinical stages (CS) I\u00adII Hodgkin's lymphoma (HL): preliminary results of the EORTC\u00adGELA H9\u00adU trial","volume":"106","author":"Ferme","year":"2005","journal-title":"Blood"},{"issue":"32","key":"10.1002\/14651858.CD007110.pub4-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2013.52.5410","article-title":"Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk Hodgkin lymphoma: a report from the Children's Oncology Group study AHOD0031","volume":"32","author":"Friedman","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD007110.pub4-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/bjh.15838","article-title":"PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial","volume":"185","author":"Pavlovsky","year":"2019","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD007110.pub4-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3816\/CLML.2010.n.028","article-title":"Risk-adapted therapy with three or six cycles of oxorubicin\/bleomycin\/vinblastine\/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study","volume":"10","author":"Pavlovsky","year":"2010","journal-title":"Clinical Lymphoma, Myeloma and Leukemia"},{"issue":"3","key":"10.1002\/14651858.CD007110.pub4-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/hon.3117","article-title":"Predictive value on advance Hodgkin lymphoma treatment outcome of end-of treatment FDG PET\/CT in the HD0607 clinical trial","volume":"41","author":"Biggi","year":"2023","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1182\/blood-2021-152292","article-title":"Lesion dissemination in baseline PET\/CT (D-MAX) and IPS score predict ABVD treatment outcome in PET-2 negative advanced-stage Hodgkin lymphoma patients enrolled in the prospective GITIL\/FIL HD0607 trial","volume":"138","author":"Gallamini","year":"2021","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/hon.105_2629","article-title":"Consolidation radiotherapy could be omitted in advanced Hodgkin lymphoma with large nodal mass in complete metabolic response after ABVD: final analysis of the randomized HD0607 trial","volume":"37","author":"Gallamini","year":"2019","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0106|cit106","unstructured":"Fondazione Italiana Linfomi ONLUS High-dose chemotherapy and stem cell transplantation, in patients PET-2 positive, after 2 courses of ABVD and comparison of RT versus no RT in PET-2 negative patients (HD0801) www.clinicaltrials.gov\/study\/NCT00784537"},{"issue":"21","key":"10.1002\/14651858.CD007110.pub4-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1182\/bloodadvances.2021005150","article-title":"Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial","volume":"5","author":"Ricardi","year":"2021","journal-title":"Blood Advances"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007110.pub4-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/0360-3016(94)90652-1","article-title":"The effect of ABVD chemotherapy with and without mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease","volume":"30","author":"Hirsch","year":"1994","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"4","key":"10.1002\/14651858.CD007110.pub4-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1200\/JCO.1996.14.4.1297","article-title":"Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease","volume":"14","author":"Hirsch","year":"1996","journal-title":"Journal of Clinical Oncology"},{"issue":"10 Suppl (Pt 1)","key":"10.1002\/14651858.CD007110.pub4-BIB0110|cit110","first-page":"673a","article-title":"12 weeks of chemotherapy (STANFORD V) and involved field radiotherapy (RT) are highly effective for bulky and advanced stage Hodgkin's disease (HD): a limited institution ECOG pilot study","volume":"88","author":"Horning","year":"1996","journal-title":"Blood"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD007110.pub4-BIB0111|cit111","first-page":"53","article-title":"A prospective trial of involved field radiation (IFRT) + chemotherapy vs. extended field radiation (EFRT) for favorable Hodgkin's disease (HD): long-term follow-up and implications for current combined modality","volume":"92","author":"Horning","year":"2007","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/01.HS9.0000890820.12468.10","article-title":"Trial in progress: individualized immunotherapy in early-stage unfavourable Hodgkin lymphoma \u2013 the investigator-initiated phase II GHSG INDIE trial","volume":"6","author":"Brockelmann","year":"2022","journal-title":"Hemasphere"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0113|cit113","unstructured":"University of Cologne Phase II trial of individualized immunotherapy in early-stage unfavorable classical Hodgkin lymphoma clinicaltrials.gov\/study\/NCT04837859"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0114|cit114","unstructured":"Phase 2 study of pembrolizumab and chemotherapy in patients with newly diagnosed classical Hodgkin lymphoma (KEYNOTE-C11) clinicaltrials.gov\/study\/NCT05008224"},{"issue":"2","key":"10.1002\/14651858.CD007110.pub4-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0360-3016(02)04596-0","article-title":"Hodgkin's disease in elderly patients (> or =60): clinical outcome and treatment strategies","volume":"56","author":"Kim","year":"2003","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"2","key":"10.1002\/14651858.CD007110.pub4-BIB0116|cit116","first-page":"S312","article-title":"Treatment reduction in patients with advanced-stage Hodgkin lymphoma and negative interim FDG-PET: final results of the international, randomized, phase 3 HD18 trial by the German Hodgkin Study Group","volume":"44","author":"Kobe","year":"2017","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"3","key":"10.1002\/14651858.CD007110.pub4-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1055\/s-2004-822627","article-title":"The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: evolution in the tradition of the DAL\/GPOH studies","volume":"216","author":"K\u00f6rholz","year":"2004","journal-title":"Klinische P\u00e4diatrie"},{"issue":"20","key":"10.1002\/14651858.CD007110.pub4-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1200\/JCO.21.00108","article-title":"Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma","volume":"39","author":"Kumar","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0119|cit119","first-page":"414","article-title":"Abbreviated chemotherapy vs chemoradiotherapy in early stage Hodgkin's disease of childhood","volume":"12","author":"Kung","year":"1993","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD007110.pub4-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/00043426-200606000-00008","article-title":"POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with stages I, IIA, IIIA Hodgkin disease: a report from the children's oncology group","volume":"28","author":"Kung","year":"2006","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007110.pub4-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1200\/JCO.2004.01.021","article-title":"Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?","volume":"22","author":"Laskar","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0122|cit122","unstructured":"Lemerle J Oberlin O Schaison G Leverger G Olive D Duffilot B Effectiveness of primary chemotherapy and low-dose radiation (RT) in childhood Hodgkin's disease (HD) [abstract] Proceedings of the American Society of Clinical Oncology 1986"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0123|cit123","first-page":"155","volume-title":"Important Advances in Oncology","author":"Longo","year":"1992"},{"issue":"3","key":"10.1002\/14651858.CD007110.pub4-BIB0124|cit124","first-page":"162","article-title":"Radiation in early-stage Hodgkin lymphoma","volume":"11","author":"Meyer","year":"2013","journal-title":"Clinical Advances in Hematology & Oncology"},{"issue":"18","key":"10.1002\/14651858.CD007110.pub4-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1200\/JCO.2002.12.007","article-title":"Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy","volume":"20","author":"Nachman","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"19","key":"10.1002\/14651858.CD007110.pub4-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.2005.05.2746","article-title":"Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials","volume":"24","author":"Noordijk","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0127|cit127","unstructured":"O'Dwyer PJ Stewart MB Wiernik PH MOPP vs radiotherapy\/MOPP for early-stage Hodgkin's disease (HD) \u2013 a six year follow-up 2nd International Conference on Malignant Lymphoma; 1984 Jun 13-16, 1984; Lugano, Switzerland"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/978-1-4613-2607-6_34","volume-title":"Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances","author":"O'Dwyer","year":"1985"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/hon.2437_69","article-title":"Brentuximab vedotin consolidation to reduce radiation use in patients with limited stage non-bulky Hodgkin lymphoma: an update from a phase 2 clinical trial","volume":"35","author":"Park","year":"2017","journal-title":"Hematological Oncology"},{"issue":"7","key":"10.1002\/14651858.CD007110.pub4-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1200\/JCO.1997.15.7.2652","article-title":"Randomized trial of CVPP for three versus six cycles in favorable-prognosis and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin's disease","volume":"15","author":"Pavlovsky","year":"1997","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD007110.pub4-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1080\/10428190701559140","article-title":"Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans","volume":"48","author":"Picardi","year":"2007","journal-title":"Leukemia & Lymphoma"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/01.HS9.0000890668.27643.97","article-title":"RADAR: an international phase III, PET response adapted, randomised trial in progress, comparing ABVD \u00b1 ISRT with brentuximab vedotin + AVD + ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma","volume":"6","author":"Radford","year":"2022","journal-title":"Hemasphere"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007110.pub4-BIB0133|cit133","first-page":"25","article-title":"Four weeks of VAPEC-B chemotherapy before involved field radiotherapy minimises the relapse rate in early stage low-risk Hodgkin's disease and is not associated with an excess of second malignancy","volume":"13","author":"Radford","year":"2002","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0134|cit134","unstructured":"Radiation-Free therapy for the Initial treatment of Good prognosis early non-bulky HL, defined by a low Metabolic Tumor Volume and a negative interim PET after 2 chemotherapy cycles \u2013 RAFTING www.clinicaltrialsregister.eu\/ctr-search\/search?query=EUCTR2020-002382-33-PL"},{"issue":"4","key":"10.1002\/14651858.CD007110.pub4-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/hon.3158","article-title":"Revisiting the predictive role of 18F-fluorodeoxyglucose positron emission tomography\/computerized tomography on treatment outcome in early-stage favorable Hodgkin lymphoma","volume":"41","author":"Gallamini","year":"2023","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0136|cit136","unstructured":"Medical University of Gdansk Radiation free chemotherapy for early Hodgkin lymphoma (RAFTING) clinicaltrials.gov\/study\/NCT04866654"},{"issue":"4","key":"10.1002\/14651858.CD007110.pub4-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s00066-013-0307-4","article-title":"Does involved field radiotherapy improve survival for children with Hodgkin's lymphoma in complete remission after chemotherapy?","volume":"189","author":"Reinartz","year":"2013","journal-title":"Strahlentherapie und Onkologie"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007110.pub4-BIB0138|cit138","first-page":"49","article-title":"Reduction of radiotherapy in early stage Hodgkin's disease: results of a randomized trial in patients PS I\/II","volume":"7","author":"R\u00fcffer","year":"1996","journal-title":"Annals of Oncology"},{"issue":"10 Suppl 1 (Pt","key":"10.1002\/14651858.CD007110.pub4-BIB0139|cit139","first-page":"abstract 626a","article-title":"Reduction of radiotherapy volume in intermediate Hodgkin's disease: interim analysis of a randomized trial in patients CS I\/II of the GHSG","volume":"92","author":"R\u00fcffer","year":"1998","journal-title":"Blood"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD007110.pub4-BIB0140|cit140","first-page":"528a","article-title":"For intermediate stage Hodgkin's disease extended field radiation after effective chemotherapy is obsolete: interim analysis of HD9 trial (GHSG)","volume":"94","author":"R\u00fcffer","year":"1999","journal-title":"Blood"},{"issue":"18","key":"10.1002\/14651858.CD007110.pub4-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.2016.70.9410","article-title":"Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials","volume":"35","author":"Sasse","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD007110.pub4-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/annonc\/3.suppl_4.S77","article-title":"Radiotherapy versus combined modality in early stages","volume":"3","author":"Specht","year":"1992","journal-title":"Annals of Oncology"},{"issue":"7 Suppl 1","key":"10.1002\/14651858.CD007110.pub4-BIB0143|cit143","first-page":"239a","article-title":"Limited chemotherapy and radiation therapy (RT) for early clinical stage (CS) Hodgkin's disease (HD). High complete remission (CR) percentage, disease free survival (DFS) and low toxicity","volume":"74","author":"Straus","year":"1989","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD007110.pub4-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","article-title":"CALGB 50604: risk-adapted treatment of non-bulky early-stage Hodgkin lymphoma based on interim PET","volume":"132","author":"Straus","year":"2018","journal-title":"Blood"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD007110.pub4-BIB0145|cit145","first-page":"52","article-title":"Selection of patients for minimal initial chemotherapy (MIC); the impact of Hasenclever score on outcome in patients receiving MIC and involved field radiotherapy for clinical stage IA\/IIA supra-diaphragmatic Hodgkin lymphoma in the UK NCRI LY07 trial","volume":"92","author":"Thistlethwaite","year":"2007","journal-title":"Haematologica"},{"issue":"Suppl 65","key":"10.1002\/14651858.CD007110.pub4-BIB0146|cit146","first-page":"40","article-title":"Six cycles of ABVD + IF\u00adRT vs. four cycles of ABVD + IF\u00adRT vs. four cycles of BEACOPP + IF\u00adRT in unfavourable supradiaphragmatic clinical stages I\u00adII Hodgkin's lymphoma: the EORTC\u00adGELA H9\u00adU randomized clinical trial (20982) in 808 patients","volume":"73","author":"Thomas","year":"2004","journal-title":"European Journal of Haematology"},{"issue":"8","key":"10.1002\/14651858.CD007110.pub4-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1200\/JCO.1997.15.8.2769","article-title":"Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study","volume":"15","author":"Weiner","year":"1997","journal-title":"Journal of Clinical Oncology"},{"issue":"26","key":"10.1002\/14651858.CD007110.pub4-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1200\/JCO.2011.41.1819","article-title":"Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma \u2013 a report from the Children's Oncology Group","volume":"30","author":"Wolden","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD007110.pub4-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/MPH.0000000000000943","article-title":"Children and adolescent Hodgkin lymphoma in Argentina: long-term results after combined ABVD and restricted radiotherapy","volume":"39","author":"Zubizarreta","year":"2017","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"issue":"2","key":"10.1002\/14651858.CD007110.pub4-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1046\/j.1365-2257.1998.00096.x","article-title":"A prospective clinical trial comparing chemotherapy, radiotherapy and combined therapy in the treatment of early stage Hodgkin's disease with bulky disease","volume":"20","author":"Aviles","year":"1998","journal-title":"Clinical & Laboratory Haematology"},{"issue":"1","key":"10.1002\/14651858.CD007110.pub4-BIB0151|cit151","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012643.pub3","article-title":"Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies","author":"Aldin","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD007110.pub4-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/ajh.25856","article-title":"Hodgkin lymphoma: a 2020 update on diagnosis, risk-stratification, and management","volume":"95","author":"Ansell","year":"2020","journal-title":"American Journal of Hematology"},{"issue":"7","key":"10.1002\/14651858.CD007110.pub4-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/1878-0261.12750","article-title":"Prevention and treatment of radiotherapy-induced side effects","volume":"14","author":"Barazzuol","year":"2020","journal-title":"Molecular Oncology"},{"issue":"18","key":"10.1002\/14651858.CD007110.pub4-BIB0154|cit154","doi-asserted-by":"publisher","first-page":"e021686","DOI":"10.1161\/JAHA.121.021686","article-title":"Radiation-induced cardiovascular disease: review of an underrecognized pathology","volume":"10","author":"Belzile-Dugas","year":"2021","journal-title":"JAMA"},{"issue":"15","key":"10.1002\/14651858.CD007110.pub4-BIB0155|cit155","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/blood-2017-10-772665","article-title":"Balancing risk and benefit in early-stage classical Hodgkin lymphoma","volume":"131","author":"Br\u00f6ckelmann","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD007110.pub4-BIB0156|cit156","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial","volume":"6","author":"Br\u00f6ckelmann","year":"2020","journal-title":"JAMA Oncology"},{"issue":"5","key":"10.1002\/14651858.CD007110.pub4-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/bjh.18130","article-title":"Navigating increasingly individualised Hodgkin lymphoma treatments to optimally balance risks and benefits","volume":"197","author":"Br\u00f6ckelmann","year":"2022","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1002\/14651858.CD007110.pub4-BIB0158|cit158","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1200\/JCO.22.02355","article-title":"Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group Phase II NIVAHL trial","volume":"41","author":"Br\u00f6ckelmann","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl","key":"10.1002\/14651858.CD007110.pub4-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"e58441b3","DOI":"10.1097\/01.HS9.0000967784.58441.b3","article-title":"S218: correlation between progression-free and overall survival in patients with classical Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomised GHSG trials","volume":"7","author":"Br\u00f6ckelmann","year":"2023","journal-title":"Hemasphere"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0160|cit160","first-page":"1380","volume-title":"Goodman and Gillman's. The Pharmacological Basis of Therapeutics","author":"Chaber","year":"2006"},{"issue":"5","key":"10.1002\/14651858.CD007110.pub4-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"27","key":"10.1002\/14651858.CD007110.pub4-BIB0162|cit162","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0163|cit163","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Deeks","year":"2019"},{"issue":"2","key":"10.1002\/14651858.CD007110.pub4-BIB0164|cit164","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3857\/roj.2018.00290","article-title":"Radiation induced secondary malignancies: a review article","volume":"36","author":"Dracham","year":"2018","journal-title":"Radiation Oncology Journal"},{"issue":"10","key":"10.1002\/14651858.CD007110.pub4-BIB0165|cit165","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.3324\/haematol.2017.167478","article-title":"Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials","volume":"102","author":"Eichenauer","year":"2017","journal-title":"Haematologica"},{"issue":"19","key":"10.1002\/14651858.CD007110.pub4-BIB0166|cit166","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","article-title":"Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group","volume":"21","author":"Engert","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"23","key":"10.1002\/14651858.CD007110.pub4-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1200\/JCO.2006.07.0482","article-title":"Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial","volume":"25","author":"Engert","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD007110.pub4-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD007110.pub4-BIB0169|cit169","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1200\/JCO.21.01281","article-title":"Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial","volume":"41","author":"Fornecker","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD007110.pub4-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/annonc\/mdf289","article-title":"Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time","volume":"13","author":"Foss Abrahamsen","year":"2002","journal-title":"Annals of Oncology"},{"issue":"4","key":"10.1002\/14651858.CD007110.pub4-BIB0171|cit171","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003187.pub2","article-title":"Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk","author":"Franklin","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD007110.pub4-BIB0172|cit172","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008814.pub2","article-title":"Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis","author":"Franklin","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD007110.pub4-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0006-2952(98)00307-4","article-title":"A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin","volume":"57","author":"Gewirtz","year":"1999","journal-title":"Biochemical Pharmacology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0174|cit174","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2023"},{"issue":"7650","key":"10.1002\/14651858.CD007110.pub4-BIB0175|cit175","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD007110.pub4-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jclinepi.2012.08.001","article-title":"GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles \u2013 continuous outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD007110.pub4-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jclinepi.2012.01.012","article-title":"GRADE guidelines: 12. Preparing summary of findings tables \u2013 binary outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jclinepi.2017.05.005","article-title":"GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence","volume":"87","author":"Guyatt","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD007110.pub4-BIB0179|cit179","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"5","key":"10.1002\/14651858.CD007110.pub4-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.ahj.2004.12.026","article-title":"Diastolic dysfunction after mediastinal irradiation","volume":"150","author":"Heidenreich","year":"2005","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0181|cit181","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0182|cit182","doi-asserted-by":"crossref","unstructured":"Higgins JP Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019) Chichester (UK) John Wiley & Sons","DOI":"10.1002\/9781119536604.ch6"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0183|cit183","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated October 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0184|cit184","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-030-32482-7_1","volume-title":"Hodgkin Lymphoma: a Comprehensive Overview","author":"Hjalgrim","year":"2020"},{"issue":"1","key":"10.1002\/14651858.CD007110.pub4-BIB0185|cit185","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-022-01281-9","article-title":"Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis","volume":"15","author":"Huang","year":"2022","journal-title":"Journal of Hematology & Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007110.pub4-BIB0186|cit186","first-page":"15","article-title":"First-line treatment of Hodgkin's lymphoma","volume":"4","author":"Klimm","year":"2005","journal-title":"Current Hematology Reports"},{"issue":"12","key":"10.1002\/14651858.CD007110.pub4-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/annonc\/mdt413","article-title":"Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions","volume":"24","author":"Klimm","year":"2013","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0188|cit188","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Lefebvre","year":"2019"},{"issue":"6","key":"10.1002\/14651858.CD007110.pub4-BIB0189|cit189","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1161\/CIRCRESAHA.115.303633","article-title":"Cardio-oncology: an update on cardiotoxicity of cancer-related treatment","volume":"118","author":"Lenneman","year":"2016","journal-title":"Circulation Research"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0190|cit190","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Li","year":"2019"},{"issue":"11","key":"10.1002\/14651858.CD007110.pub4-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting","volume":"7","author":"Lister","year":"1989","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0192|cit192","doi-asserted-by":"publisher","first-page":"736261","DOI":"10.1155\/2011\/736261","article-title":"Clinical, molecular, and environmental risk factors for Hodgkin lymphoma","volume":"2011","author":"Maggioncalda","year":"2011","journal-title":"Advances in Hematology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0193|cit193","first-page":"76","volume-title":"Principles and Practice of Radiation Oncology","author":"McBride","year":"2008"},{"issue":"1127","key":"10.1002\/14651858.CD007110.pub4-BIB0194|cit194","doi-asserted-by":"publisher","first-page":"20210448","DOI":"10.1259\/bjr.20210448","article-title":"Total tumor burden in lymphoma \u2013 an evolving strong prognostic parameter","volume":"94","author":"Meignan","year":"2021","journal-title":"British Journal of Radiology"},{"issue":"10","key":"10.1002\/14651858.CD007110.pub4-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0196|cit196","first-page":"61","volume-title":"Hodgkin's Disease","author":"Mueller","year":"1999"},{"issue":"7","key":"10.1002\/14651858.CD007110.pub4-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.clon.2015.03.005","article-title":"Involved node, site, field and residual volume radiotherapy for lymphoma: a comparison of organ at risk dosimetry and second malignancy risks","volume":"27","author":"Murray","year":"2015","journal-title":"Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD007110.pub4-BIB0198|cit198","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1200\/JCO.2009.24.8062","article-title":"Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy","volume":"28","author":"O'Brien","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0199|cit199","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Page","year":"2019"},{"issue":"24","key":"10.1002\/14651858.CD007110.pub4-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"11","key":"10.1002\/14651858.CD007110.pub4-BIB0201|cit201","first-page":"177","article-title":"Hodgkin's lymphoma in adults: diagnosis, treatment and follow-up","volume":"110","author":"Rancea","year":"2013","journal-title":"Deutsches Arzteblatt International"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0202|cit202","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"issue":"2","key":"10.1002\/14651858.CD007110.pub4-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.cegh.2018.05.005","article-title":"Interpretation of subgroup analyses in systematic reviews: a tutorial","volume":"7","author":"Richardson","year":"2019","journal-title":"Clinical Epidemiology and Global Health"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0204|cit204","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014.","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"issue":"8","key":"10.1002\/14651858.CD007110.pub4-BIB0205|cit205","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.2016.70.9410","article-title":"Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin study group HD7, HD8, HD10, and HD11 trials","volume":"35","author":"Sasse","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0206|cit206","first-page":"464","volume-title":"Harrison's Principles of Internal Medicine","author":"Sausville","year":"2005"},{"issue":"1","key":"10.1002\/14651858.CD007110.pub4-BIB0207|cit207","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1038\/sj.cdd.4401456","article-title":"Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance","volume":"11","author":"Schmidt","year":"2004","journal-title":"Cell Death & Differentiation"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0208|cit208","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated October 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook"},{"issue":"7","key":"10.1002\/14651858.CD007110.pub4-BIB0209|cit209","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nature Biotechnology"},{"issue":"1","key":"10.1002\/14651858.CD007110.pub4-BIB0210|cit210","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.ijrobp.2019.06.446","article-title":"Consolidation radiotherapy following PET complete response in early-stage Hodgkins lymphoma: a meta-analysis","volume":"105","author":"Shaikh","year":"2019","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"2","key":"10.1002\/14651858.CD007110.pub4-BIB0211|cit211","first-page":"116","article-title":"Hodgkin lymphoma: a review and update on recent progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"1","key":"10.1002\/14651858.CD007110.pub4-BIB0212|cit212","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010533.pub2","article-title":"Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma","author":"Sickinger","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jclinepi.2019.10.015","article-title":"GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in Summary of findings tables and Evidence Profiles","volume":"118","author":"Skoetz","year":"2019","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD007110.pub4-BIB0214|cit214","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/0959-8049(92)90243-U","article-title":"Tumour burden as the main indicator of prognosis in Hodgkin's disease","volume":"28","author":"Specht","year":"1992","journal-title":"European Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD007110.pub4-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/PPO.0000000000000332","article-title":"Radiotherapy for Hodgkin lymphoma: reducing toxicity while maintaining efficacy","volume":"24","author":"Specht","year":"2018","journal-title":"Cancer Journal: the Journal of Principles & Practice of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD007110.pub4-BIB0216|cit216","doi-asserted-by":"publisher","first-page":"100950","DOI":"10.1016\/j.adro.2022.100950","article-title":"Risk of bacterial, viral, and fungal infections in patients with solid malignant tumors treated with curative intent radiation therapy","volume":"7","author":"Terrones-Campos","year":"2022","journal-title":"Advances in Radiation Oncology"},{"issue":"16","key":"10.1002\/14651858.CD007110.pub4-BIB0217|cit217","first-page":"1745","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0218|cit218","doi-asserted-by":"publisher","first-page":"1067289","DOI":"10.3389\/fonc.2023.1067289","article-title":"Advances in the treatment of Hodgkin lymphoma: current and future approaches","volume":"13","author":"Ullah","year":"2023","journal-title":"Frontiers in Oncology"},{"issue":"4","key":"10.1002\/14651858.CD007110.pub4-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/hon.939","article-title":"Fertility preservation after chemotherapy for Hodgkin lymphoma","volume":"28","author":"Kaaij","year":"2010","journal-title":"Hematology Oncology"},{"issue":"2","key":"10.1002\/14651858.CD007110.pub4-BIB0220|cit220","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1517\/14728214.2014.912277","article-title":"An update on emerging drugs for Hodgkin lymphoma","volume":"19","author":"Tresckow","year":"2014","journal-title":"Expert Opinion on Emerging Drugs"},{"issue":"9","key":"10.1002\/14651858.CD007110.pub4-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1002\/sim.7242","article-title":"Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility","volume":"36","author":"Walter","year":"2017","journal-title":"Statistics in Medicine"},{"issue":"5","key":"10.1002\/14651858.CD007110.pub4-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.seminoncol.2010.09.005","article-title":"Immune checkpoint proteins: a new therapeutic paradigm for cancer \u2013 preclinical background: CTLA-4 and PD-1 blockade","volume":"37","author":"Weber","year":"2010","journal-title":"Seminars in Oncology"},{"issue":"12","key":"10.1002\/14651858.CD007110.pub4-BIB0223|cit223","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1080\/10428194.2022.2105325","article-title":"Patterns of care and outcomes of early stage I\u2013II Hodgkin lymphoma treated with or without radiation therapy","volume":"63","author":"Weil","year":"2022","journal-title":"Leukemia & Lymphoma"},{"issue":"1","key":"10.1002\/14651858.CD007110.pub4-BIB0224|cit224","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1016\/S1470-2045(14)70375-4","article-title":"Outcomes and endpoints in trials of cancer treatment: the past, present, and future","volume":"16","author":"Wilson","year":"2015","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD007110.pub4-BIB0225|cit225","doi-asserted-by":"publisher","first-page":"485071","DOI":"10.1155\/2015\/485071","article-title":"The role of radiotherapy in Hodgkin's lymphoma: what has been achieved during the last 50 years?","volume":"2015","author":"Witkowska","year":"2015","journal-title":"BioMed Research International"},{"issue":"5","key":"10.1002\/14651858.CD007110.pub4-BIB0226|cit226","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.ijrobp.2008.12.016","article-title":"Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients","volume":"73","author":"Wo","year":"2009","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"4","key":"10.1002\/14651858.CD007110.pub4-BIB0227|cit227","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007110.pub3","article-title":"Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma","author":"Blank","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD007110.pub4-BIB0228|cit228","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007110.pub2","article-title":"Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma","author":"Herbst","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD007110.pub4-BIB0229|cit229","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007110","article-title":"Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma","author":"Rehan","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T13:49:22Z","timestamp":1781185762000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007110.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":229,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007110.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,2]]}}}